- Home
- RERE vs QURE Comparison
RERE vs QURE Comparison
Compare RERE & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- QURE
- Stock Information
- Founded
- RERE 2011
- QURE 1998
- Country
- RERE China
- QURE Netherlands
- Employees
- RERE N/A
- QURE N/A
- Industry
- RERE Other Specialty Stores
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- QURE Health Care
- Exchange
- RERE Nasdaq
- QURE Nasdaq
- Market Cap
- RERE 678.4M
- QURE 691.2M
- IPO Year
- RERE 2021
- QURE 2007
- Fundamental
- Price
- RERE $2.92
- QURE $12.84
- Analyst Decision
- RERE
- QURE Strong Buy
- Analyst Count
- RERE 0
- QURE 8
- Target Price
- RERE N/A
- QURE $39.43
- AVG Volume (30 Days)
- RERE 654.1K
- QURE 820.4K
- Earning Date
- RERE 03-11-2025
- QURE 03-03-2025
- Dividend Yield
- RERE N/A
- QURE N/A
- EPS Growth
- RERE N/A
- QURE N/A
- EPS
- RERE N/A
- QURE N/A
- Revenue
- RERE $2,188,701,829.00
- QURE $28,587,000.00
- Revenue This Year
- RERE $28.08
- QURE $153.92
- Revenue Next Year
- RERE $25.05
- QURE N/A
- P/E Ratio
- RERE N/A
- QURE N/A
- Revenue Growth
- RERE 27.16
- QURE N/A
- 52 Week Low
- RERE $1.11
- QURE $3.73
- 52 Week High
- RERE $3.70
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- RERE 51.16
- QURE 38.20
- Support Level
- RERE $2.92
- QURE $12.72
- Resistance Level
- RERE $3.01
- QURE $14.42
- Average True Range (ATR)
- RERE 0.16
- QURE 0.85
- MACD
- RERE -0.01
- QURE -0.26
- Stochastic Oscillator
- RERE 52.21
- QURE 7.26
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.